Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01195571 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age
A Phase 1 study of Cytomegalovirus, sponsored by CMV Research Foundation.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01195571 is a Phase 1 study of Cytomegalovirus that has completed, run by CMV Research Foundation. The registered enrollment target is 36 participants, below the 215-participant average among 5 other Cytomegalovirus trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01195571, a Phase 1 study of Cytomegalovirus, has completed, sponsored by CMV Research Foundation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to test the safety and tolerability of four new investigational Cytomegalovirus (CMV) vaccines (Towne-Toledo 1, 2, 3, 4) in healthy male volunteers who are CMV negative. CMV is a common virus, infecting 50-80% of adults in the United States by the age of twenty-one. CMV does not usually cause illness in adults or children. However, CMV can be a cause of deafness and mental retardation in a child if a mother is infected during pregnancy. It also can be a serious illness in patients with impaired immunity (decreased ability to fight infection).
Conditions Studied
Interventions
- BIOLOGICAL cmv vaccine
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01195571
The ClinicalTrials.gov registry entry for NCT01195571 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 5 other Cytomegalovirus trials with a reported enrollment target (83% lower). The listed sponsor is CMV Research Foundation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cytomegalovirus appearing as the primary indexed condition, and to 1 intervention - of which cmv vaccine is the first listed.
NCT01195571 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT01195571 about?
NCT01195571 is a clinical study titled "Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age". The purpose of this research study is to test the safety and tolerability of four new investigational Cytomegalovirus (CMV) vaccines (Towne-Toledo 1, 2, 3, 4) in healthy male volunteers who are CMV negative. CMV is a common virus, infecting 50-80% of adults in the United States by the age of twenty-...
What is the current status of trial NCT01195571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2010-09. Estimated completion is 2014-10.
What conditions does trial NCT01195571 study?
This clinical trial studies the following conditions: Cytomegalovirus.
What interventions are being tested in trial NCT01195571?
The interventions under investigation include: cmv vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01195571?
This trial is sponsored by CMV Research Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01195571 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
ACTIVE NOT RECRUITING · Phase 1
-
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
RECRUITING · Phase 2
-
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
RECRUITING · Early Phase 1
-
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
RECRUITING · Phase 4
-
Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.